Brian J. Druker - Publications

Affiliations: 
Oregon Health and Science University, Portland, OR 

379 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Sanford JA, Wang Y, Hansen JR, Gritsenko MA, Weitz KK, Sagendorf TJ, Tognon CE, Petyuk VA, Qian WJ, Liu T, Druker BJ, Rodland KD, Piehowski PD. Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality. Journal of the American Society For Mass Spectrometry. PMID 34813325 DOI: 10.1021/jasms.1c00169  1
2021 Zhao H, Pomicter AD, Eiring AM, Franzini A, Ahmann J, Hwang JY, Senina AV, Helton B, Iyer SM, Yan D, Khorashad JS, Zabriskie MS, Agarwal A, Redwine HM, Bowler AD, ... ... Druker BJ, et al. MS4A3 Promotes Differentiation in Chronic Myeloid Leukemia by Enhancing Common β Chain Cytokine Receptor Endocytosis. Blood. PMID 34780648 DOI: 10.1182/blood.2021011802  1
2021 Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz JM, Borate U, Wilmot B, Tognon CE, Bock AM, Pollyea DA, Radhakrishnan SM, Radhakrishnan S, Patel PA, ... ... Druker BJ, et al. Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult AML patients. Blood. PMID 34482403 DOI: 10.1182/blood.2021011354  1
2021 Yenerall P, Kollipara RK, Avila K, Peyton M, Eide CA, Bottomly D, McWeeney SK, Liu Y, Westover KD, Druker BJ, Minna JD, Kittler R. Lentiviral-driven discovery of cancer drug resistance mutations. Cancer Research. PMID 34301758 DOI: 10.1158/0008-5472.CAN-21-1153  1
2021 Tsumura AM, Druker BJ, Brewer D, Press R, Braun TP. BCR-ABL+ Chronic Myeloid Leukemia Arising in a Family With Inherited ANKRD26-Related Thrombocytopenia. Jco Precision Oncology. 5. PMID 34250402 DOI: 10.1200/PO.20.00318  1
2021 Leonard J, Wolf JS, Degnin M, Eide CA, LaTocha D, Lenz K, Wilmot B, Mullighan CG, Loh M, Hunger SP, Druker BJ, Loriaux MM, Tyner JW, Chang BH. Aurora A kinase as a target for therapy in rearranged acute lymphoblastic leukemia. Haematologica. PMID 34233449 DOI: 10.3324/haematol.2021.278692  1
2021 Joshi SK, Nechiporuk T, Bottomly D, Piehowski PD, Reisz JA, Pittsenbarger J, Kaempf A, Gosline SJC, Wang YT, Hansen JR, Gritsenko MA, Hutchinson C, Weitz KK, Moon J, Cendali F, ... ... Druker BJ, et al. The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. Cancer Cell. PMID 34171263 DOI: 10.1016/j.ccell.2021.06.003  1
2021 Mims AS, Kohlschmidt J, Borate U, Blachly JS, Orwick S, Eisfeld AK, Papaioannou D, Nicolet D, Mrόzek K, Stein E, Bhatnagar B, Stone RM, Kolitz JE, Wang ES, Powell BL, ... ... Druker BJ, et al. A precision medicine classification for treatment of acute myeloid leukemia in older patients. Journal of Hematology & Oncology. 14: 96. PMID 34162404 DOI: 10.1186/s13045-021-01110-5  1
2021 Joshi SK, Sharzehi S, Pittsenbarger J, Bottomly D, Tognon CE, McWeeney SK, Druker BJ, Traer E. A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance. American Journal of Hematology. PMID 33780043 DOI: 10.1002/ajh.26174  1
2021 Bencomo-Alvarez AE, Rubio AJ, Olivas IM, Gonzalez MA, Ellwood R, Fiol CR, Eide CA, Lara JJ, Barreto-Vargas C, Jave-Suarez LF, Nteliopoulos G, Reid AG, Milojkovic D, Druker BJ, Apperley J, et al. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene. PMID 33712704 DOI: 10.1038/s41388-021-01732-6  1
2021 Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, ... ... Druker BJ, et al. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Research. PMID 33707228 DOI: 10.1101/gr.269233.120  1
2021 Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, Kim W, Kuo CJ, McManus M, B Mills G, Mo X, et al. An expanded universe of cancer targets. Cell. 184: 1142-1155. PMID 33667368 DOI: 10.1016/j.cell.2021.02.020  1
2021 Carratt SA, Brewer D, Maxson JE, Druker BJ, Braun TP. Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report. Biomarker Research. 9: 8. PMID 33516272 DOI: 10.1186/s40364-021-00261-4  1
2021 Scopim-Ribeiro R, Machado-Neto JA, Eide CA, Coelho-Silva JL, Fenerich BA, Fernandes JC, Scheucher PS, Savage Stevens SL, de Melo Campos P, Olalla Saad ST, de Carvalho Palma L, de Figueiredo-Pontes LL, Simões BP, Rego EM, Tognon CE, ... Druker BJ, et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs. PMID 33403501 DOI: 10.1007/s10637-020-01028-8  1
2020 Braun TP, Druker BJ. Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse. Jama Oncology. PMID 33180121 DOI: 10.1001/jamaoncol.2020.5772  1
2020 Rosenberg MW, Watanabe-Smith K, Tyner JW, Tognon CE, Druker BJ, Borate U. Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients. Oncotarget. 11: 2807-2818. PMID 32754299 DOI: 10.18632/Oncotarget.27656  1
2020 Lamble AJ, Kosaka Y, Laderas T, Maffit A, Kaempf A, Brady LK, Wang W, Long N, Saultz JN, Mori M, Soong D, LeFave CV, Huang F, Adams H, Loriaux MM, ... ... Druker BJ, et al. Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 32513686 DOI: 10.1073/Pnas.1916206117  1
2020 Braun TP, Coblentz C, Smith BM, Coleman DJ, Schonrock Z, Carratt SA, Callahan RL, Maniaci B, Druker BJ, Maxson JE. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 32471953 DOI: 10.1073/Pnas.1918307117  1
2020 Joshi SK, Keck JM, Eide CA, Bottomly D, Traer E, Tyner JW, McWeeney SK, Tognon CE, Druker BJ. ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia. Leukemia. PMID 32366937 DOI: 10.1038/S41375-020-0844-7  1
2020 Joshi SK, Qian K, Bisson WH, Watanabe-Smith K, Huang A, Bottomly D, Traer E, Tyner JW, McWeeney SK, Davare M, Druker BJ, Tognon CE. Discovery and Characterization of Targetable NTRK Point Mutations in Hematologic Neoplasms. Blood. PMID 32315394 DOI: 10.1182/Blood.2019003691  1
2020 Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy. 5: 5. PMID 32296029 DOI: 10.1038/S41392-019-0102-5  1
2020 Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 37: 530-542. PMID 32289275 DOI: 10.1016/J.Ccell.2020.03.006  1
2020 Eide CA, Kurtz SE, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Chang BH, Danilov AV, Tyner JW. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 32094466 DOI: 10.1038/S41375-020-0764-6  1
2020 Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy. 5: 5. PMID 31993221 DOI: 10.1038/s41392-019-0102-5  1
2020 Barnes EJ, Leonard J, Medeiros B, Druker BJ, Tognon CE. Functional characterization of two rare BCR-FGFR1+ leukemias. Cold Spring Harbor Molecular Case Studies. PMID 31980503 DOI: 10.1101/mcs.a004838  1
2020 Piehowski PD, Wang Y, Sanford JA, Hansen JR, Gritsenko MA, Petyuk VA, Weitz KK, Tognon C, Qian W, Liu T, Druker BJ, Rodland KD. Abstract 5125: Evaluation of differential peptide loading on TMT-based proteomic on phosphoproteomic data quality in an AML model Cancer Research. 80: 5125-5125. DOI: 10.1158/1538-7445.Am2020-5125  1
2019 Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, ... ... Druker BJ, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900895. PMID 31880950 DOI: 10.1200/Jco.19.00895  1
2019 Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, ... ... Druker BJ, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. The New England Journal of Medicine. 381: 2315-2326. PMID 31826340 DOI: 10.1056/Nejmoa1902328  1
2019 Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, Smith BM, Nevonen K, Davis B, Garcia B, LaTocha D, Weeder BR, Grzadkowski MR, Estabrook JC, Manning HG, ... ... Druker BJ, et al. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. Nature Communications. 10: 5455. PMID 31784538 DOI: 10.1038/S41467-019-13364-2  1
2019 Agarwal A, Bolosky WJ, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ. Differentiation of leukemic blasts is not completely blocked in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. PMID 31754026 DOI: 10.1073/Pnas.1904091116  1
2019 Rivera-Mulia JC, Sasaki T, Trevilla-Garcia C, Nakamichi N, Knapp DJHF, Hammond CA, Chang BH, Tyner JW, Devidas M, Zimmerman J, Klein KN, Somasundaram V, Druker BJ, Gruber TA, Koren A, et al. Replication timing alterations in leukemia affect clinically relevant chromosome domains. Blood Advances. 3: 3201-3213. PMID 31698451 DOI: 10.1182/Bloodadvances.2019000641  1
2019 Joshi SK, Davare MA, Druker BJ, Tognon CE. Revisiting NTRKs as an emerging oncogene in hematological malignancies. Leukemia. PMID 31551508 DOI: 10.1038/S41375-019-0576-8  1
2019 Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, Schultz AR, Clair P, Bowler AD, Pomicter AD, Yan D, Senina AV, Qiang W, Kelley TW, Szankasi P, ... ... Druker BJ, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. PMID 31543464 DOI: 10.1016/J.Ccell.2019.08.004  1
2019 Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, ... ... Druker BJ, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/Blood.2019000611  1
2019 Burd A, Schilsky RL, Byrd JC, Levine RL, Papadimitrakopoulou VA, Herbst RS, Redman MW, Druker BJ, Gandara DR. Challenges and approaches to implementing master/basket trials in oncology. Blood Advances. 3: 2237-2243. PMID 31337605 DOI: 10.1182/Bloodadvances.2019031229  1
2019 Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation. Cancer Research. PMID 31311809 DOI: 10.1158/0008-5472.Can-19-1236  1
2019 Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. PMID 31209280 DOI: 10.1038/S41375-019-0512-Y  1
2019 Dunlap JB, Leonard J, Rosenberg M, Cook R, Press R, Fan G, Raess P, Druker BJ, Traer E. The combination of NPM1, DNMT3A and IDH1/2 mutations leads to inferior overall survival in AML. American Journal of Hematology. PMID 31145495 DOI: 10.1002/Ajh.25517  1
2019 Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, et al. The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells. Cancer Discovery. PMID 31048320 DOI: 10.1158/2159-8290.Cd-19-0125  1
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribeiro R, Viola SK, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. Correction: FGF2-FGFR1 signaling regulates release of leukemia-protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30924767 DOI: 10.7554/Elife.47174  1
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/Elife.40033  1
2019 Javidi-Sharifi N, Martinez J, English I, Joshi SK, Scopim-Ribiero R, Edwards DK, Agarwal A, Lopez C, Jorgens D, Tyner JW, Druker BJ, Traer E. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. Elife. 8. PMID 30720426 DOI: 10.7554/Elife.40033  1
2019 Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, et al. Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. PMID 30692122 DOI: 10.1182/Blood-2018-10-881557  1
2019 Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, Ozawa K, Shentu W, Brown E, Shirai T, McCarty OJ, Ruggeri Z, Moslehi J, Chen J, Druker BJ, et al. Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. PMID 30692122 DOI: 10.1182/Blood-2018-10-881557  1
2019 Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, ... ... Druker BJ, et al. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms. Nature Communications. 10: 244. PMID 30651561 DOI: 10.1038/S41467-018-08263-X  1
2019 Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, McWeeney SK, Druker BJ, Cogle CR. Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. Leukemia Research. PMID 30642575 DOI: 10.1016/J.Leukres.2018.11.010  1
2019 Eide CA, Kurtz SE, Kaempf A, Long N, Leonard J, Chang BH, Mori M, Druker BJ, Tyner JW. Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia Blood. 134: 3950-3950. DOI: 10.1182/Blood-2019-131288  1
2019 Bolosky W, Wilson DB, Eide CA, Olson SB, Fan G, Druker BJ, Agarwal A. Mathematical and Experimental Evidence That Differentiation of Leukemic Blasts in Acute Myeloid Leukemia Is Not Completely Blocked Blood. 134: 1435-1435. DOI: 10.1182/Blood-2019-131007  1
2019 Giacopelli B, Wang M, Cleary AC, Wu Y, Schultz AR, Blachly JS, Eisfeld A, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC. DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia Blood. 134: 1413-1413. DOI: 10.1182/Blood-2019-126212  1
2019 Kurtz SE, Eide CA, Kaempf A, Long N, Agarwal A, Tognon CE, Mori M, Druker BJ, Tyner JW. Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia Blood. 134: 878-878. DOI: 10.1182/Blood-2019-126020  1
2019 Braun T, Lusardi T, Enright T, Schonrock Z, Coblentz C, Mohamed H, Druker BJ, Maxson JE. Single Cell RNA Sequencing Identifies a Crucial Role for ASXL1 in Neutrophil Development Blood. 134: 212-212. DOI: 10.1182/Blood-2019-125022  1
2019 Braun T, Coblentz C, Carratt SA, Okhovat M, Foley A, Schonrock Z, Nevonen K, Ries RE, McWeeney SK, Nerlov C, Meshinchi S, Carbone L, Druker BJ, Maxson JE. Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML Blood. 134: 543-543. DOI: 10.1182/Blood-2019-124773  1
2019 Radich JP, Larson RA, Kantarjian HM, Deininger MW, Ibarz JP, DeAngelo DJ, Branford S, Sadek I, Chaturvedi S, Sondhi M, Wall M, Mishra K, Purkayastha D, Shrestha A, Obourn V, ... ... Druker BJ, et al. Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd Blood. 134: 665-665. DOI: 10.1182/Blood-2019-124716  1
2019 Piehowski PD, McDermott JE, Hansen JR, Savage SL, Tognon CE, Agarwal A, Tyner JW, Druker BJ, Rodland KD. Abstract 4538: Global and phosphoproteomic analysis of AML cell line response to phosphatase inhibitor treatment Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4538  1
2019 Nechiporuk T, Kurtz SE, Nikolova O, d'Almeida A, Watanabe-Smith K, Rosenberg M, Druker B, Tyner JW, McWeeney SK. Abstract 325: A genome-wide CRISPR screen on AML cells reveals the TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-325  1
2019 Vijay V, Meacham A, Katzell L, Winer A, Terrell J, Archibald V, Bubenik J, Riva A, Boatwright J, Tognon C, Tyner J, Druker B, Cogle C. Abstract 3042: Splicing repressorHNRNPCis an indispensable and 'druggable' target in acute myeloid leukemia Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3042  1
2019 Joshi SK, Christy S, Ribeiro RS, McWeeney S, Tyner JW, Tognon CE, Druker BJ, Traer E. Abstract 926: Extrinsic and intrinsic activation of RAS/MAPK signaling enables resistance to FLT3 inhibitor, gilteritinib, in acute myeloid leukemia Cancer Research. 79: 926-926. DOI: 10.1158/1538-7445.Am2019-926  1
2019 Zhang H, Local A, Tyner JW, Kurtz SE, Wilmot B, Mcweeney S, Druker BJ, Howell SB, Rice WG. Abstract 1323: CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients Cancer Research. 79: 1323-1323. DOI: 10.1158/1538-7445.Am2019-1323  1
2018 Berman E, Druker BJ, Burwick R. Reply to N. Cerveira et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801004. PMID 30422739 DOI: 10.1200/Jco.18.01004  1
2018 Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, ... ... Druker BJ, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. PMID 30333627 DOI: 10.1038/S41586-018-0623-Z  1
2018 Davare MA, Henderson JJ, Agarwal A, Wagner JP, Iyer SR, Shah N, Woltjer R, Somwar R, Gilheeney SW, deCarvalho AC, Mikkelsen T, Van Meir EG, Ladanyi M, Druker BJ. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30171048 DOI: 10.1158/1078-0432.Ccr-18-1052  1
2018 Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW. Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia. Leukemia. PMID 30082821 DOI: 10.1038/s41375-018-0225-7  1
2018 Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget. 9: 24576-24589. PMID 29872489 DOI: 10.18632/Oncotarget.25191  1
2018 Berman E, Druker BJ, Burwick R. Reply to D.M. Ross et al and V. Florou et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018791806. PMID 29851547 DOI: 10.1200/Jco.2018.79.1806  1
2018 Hosseini MM, Kurtz SE, Abdelhamed S, Mahmood S, Davare MA, Kaempf A, Elferich J, McDermott JE, Liu T, Payne SH, Shinde U, Rodland KD, Mori M, Druker BJ, Singer JW, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. PMID 29743719 DOI: 10.1038/S41375-018-0112-2  1
2018 Watanabe-Smith K, Druker BJ, Tyner JW, Edwards DK. Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia. Haematologica. PMID 29567769 DOI: 10.3324/Haematol.2018.190926  1
2018 Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, et al. Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms. Cell Death & Disease. 9: 311. PMID 29472557 DOI: 10.1038/S41419-017-0256-4  1
2018 Berman E, Druker BJ, Burwick R. Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017772574. PMID 29447062 DOI: 10.1200/Jco.2017.77.2574  1
2018 Braun T, Foley A, Druker BJ, Maxson JE. Function of ASXL1 Mutations in Chronic Neutrophilic Leukemia Blood. 132: 3067-3067. DOI: 10.1182/Blood-2018-99-119213  1
2018 Chang BH, Leonard J, Wolf J, Degnin M, Lenz K, Wilmot B, Mullighan CG, Loh ML, Hunger SP, Tyner JW, Druker BJ. Significant In Vivo Sensitivity to Aurora Kinase Inhibition in TCF3-Hlf rearranged Acute Lymphoblastic Leukemia Blood. 132: 4026-4026. DOI: 10.1182/Blood-2018-99-115706  1
2018 Schultz AR, Jacob T, Eide CA, Savage SL, Mori M, Tyner JW, Tognon CE, Vu TQ, Druker BJ. Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging Blood. 132: 4248-4248. DOI: 10.1182/Blood-2018-99-115387  1
2018 Joshi SK, Qian K, Wagner JP, Davare MA, Tognon CE, Druker BJ. Abstract 970: Transforming NTRK2 and NTRK3 mutations as potential drivers of leukemia Cancer Research. 78: 970-970. DOI: 10.1158/1538-7445.Am2018-970  1
2018 Kurtz SE, Watanabe-Smith K, Bottomly D, Wilmot B, Mcweeney S, Local A, Zhang H, Howell S, Rice W, Druker BJ, Tyner JW. Abstract 791: CG'806, a first-in-class pan-FLT3/pan-BTK inhibitor, demonstrates superiority to other FLT3 and BTK inhibitors against primary patient samples Cancer Research. 78: 791-791. DOI: 10.1158/1538-7445.Am2018-791  1
2018 White BS, Khan SA, Ammad-ud-din M, Potdar S, Mason MJ, Tognon CE, Druker BJ, Heckman CA, Kallioniemi OP, Kurtz SE, Porkka K, Tyner JW, Aittokallio T, Wennerberg K, Guinney J. Abstract 3883: Gene expression predicts ex vivo drug sensitivity in acute myeloid leukemia Cancer Research. 78: 3883-3883. DOI: 10.1158/1538-7445.Am2018-3883  1
2018 Pirrotte P, David V, Sharma R, Wai DH, Tognon C, Druker B, Aleem EA. Abstract 2705: Functional proteomics to reveal distinct signature for acute myeloid leukemia subtypes Cancer Research. 78: 2705-2705. DOI: 10.1158/1538-7445.Am2018-2705  1
2018 Gupta P, Zhang G, Barbuti AM, Ding K, Pan J, Druker BJ, Chen Z. Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia Cancer Research. 78: 1980-1980. DOI: 10.1158/1538-7445.Am2018-1980  1
2017 Merchant AA, Jorapur A, McManus A, Liu R, Krasnoperov V, Chaudhry P, Singh M, Harton L, Agajanian M, Kim M, Triche TJ, Druker BJ, Tyner JW, Gill PS. EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT. Blood Advances. 1: 1635-1644. PMID 29296810 DOI: 10.1182/Bloodadvances.2017005694  1
2017 Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, et al. A novel AGGF1-PDGFRβ fusion in pediatric T-cell acute lymphoblastic leukemia. Haematologica. PMID 29284681 DOI: 10.3324/Haematol.2017.165282  1
2017 Mitchell R, Hopcroft LEM, Baquero P, Allan EK, Hewit K, James D, Hamilton G, Mukhopadhyay A, O'Prey J, Hair A, Melo JV, Chan E, Ryan KM, Maguer-Satta V, Druker BJ, et al. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. Journal of the National Cancer Institute. PMID 29165716 DOI: 10.1093/Jnci/Djx236  1
2017 Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, et al. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29078326 DOI: 10.1073/Pnas.1708268114  1
2017 Degnin M, Agarwal A, Tarlock K, Meshinchi S, Druker BJ, Tognon CE. Novel Method Enabling the Use of Cryopreserved Primary Acute Myeloid Leukemia Cells in Functional Drug Screens. Journal of Pediatric Hematology/Oncology. PMID 28906323 DOI: 10.1097/Mph.0000000000000946  1
2017 Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, ... ... Druker BJ, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences of the United States of America. PMID 28784769 DOI: 10.1073/Pnas.1703094114  1
2017 Eide CA, Druker BJ. Understanding cancer from the stem cells up. Nature Medicine. 23: 656-657. PMID 28586338 DOI: 10.1038/Nm.4353  1
2017 Sasaki T, Rivera-Mulia JC, Vera D, Zimmerman J, Das S, Padget M, Nakamichi N, Chang BH, Tyner J, Druker BJ, Weng AP, Civin CI, Eaves CJ, Gilbert DM. Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia. Experimental Hematology. PMID 28433605 DOI: 10.1016/J.Exphem.2017.04.004  1
2017 Reed JC, Druker BJ. Peter C. Nowell (1928-2016). Proceedings of the National Academy of Sciences of the United States of America. PMID 28416695 DOI: 10.1073/Pnas.1705526114  0.01
2017 Henderson JJ, Wagner JP, Hofmann NE, Eide CA, Cho YJ, Druker BJ, Davare MA. Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line. Pediatric Blood & Cancer. PMID 28409891 DOI: 10.1002/Pbc.26553  1
2017 Burwick RM, Kuo K, Brewer D, Druker BJ. Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy. Obstetrics and Gynecology. PMID 28383372 DOI: 10.1097/Aog.0000000000001972  1
2017 Carey A, Edwards DK, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A. Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia. Cell Reports. 18: 3204-3218. PMID 28355571 DOI: 10.1016/J.Celrep.2017.03.018  1
2017 Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England Journal of Medicine. 376: 917-927. PMID 28273028 DOI: 10.1056/Nejmoa1609324  1
2017 Watanabe-Smith K, Godil J, Agarwal A, Tognon C, Druker B. Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations. Oncotarget. PMID 28208123 DOI: 10.18632/Oncotarget.15392  1
2017 Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, et al. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget. PMID 28186983 DOI: 10.18632/Oncotarget.15146  1
2017 Kurtz SE, Wilmot B, Mcweeney S, Local A, Zhang H, Howell S, Rice W, Druker BJ, Tyner JW. CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples Blood. 130: 4626-4626. DOI: 10.1182/Blood.V130.Suppl_1.4626.4626  1
2017 Neto JAM, Ribeiro RS, Coelho-Silva JL, Eide CA, Fenerich BA, Fernandes JC, Alves APNR, Scheucher PS, Tognon CE, Figueiredo-Pontes LL, Druker BJ, Rego EM, Traina F. Metformin Reduces Tumor Burden and Splenomegaly in JAK2V617F Murine Models Blood. 130: 4222-4222. DOI: 10.1182/Blood.V130.Suppl_1.4222.4222  1
2017 Drusbosky LM, Turcotte M, Castillo P, Vidva R, Gera S, Sauban M, Bhargav P, Deep P, Kapoor S, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, et al. Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study Blood. 130: 3909-3909. DOI: 10.1182/Blood.V130.Suppl_1.3909.3909  1
2017 Drusbosky LM, Vidva R, Gera S, Lakshminarayana AV, Shyamasundar VP, Agrawal AK, Talawdekar A, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR. Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 130: 3908-3908. DOI: 10.1182/Blood.V130.Suppl_1.3908.3908  1
2017 Drusbosky LM, Vidva R, Gera S, Das A, Tiwari KK, Joseph V, Mohapatra S, Lunkad N, Abbasi T, Vali S, Tognon CE, Kurtz SE, Tyner JW, Druker BJ, Cogle CR. Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study Blood. 130: 3907-3907. DOI: 10.1182/Blood.V130.Suppl_1.3907.3907  1
2017 Drusbosky LM, Hawkins KE, Leather HL, Murthy HS, Farhadfar N, Wingard JR, Norkin M, Brown RA, Hiemenz JW, Castillo P, Horn BN, Kumar A, Singh NK, Kumar C, Vasista S, ... ... Druker BJ, et al. A Genomic Signature Predicting Venetoclax Treatment Response in Acute Myeloid Leukemia (AML) Identified By Protein Network Mapping and Validated By Ex Vivo Ddrug Sensitivity Testing Blood. 130: 2707-2707. DOI: 10.1182/Blood.V130.Suppl_1.2707.2707  1
2017 Kurtz SE, Eide CA, Kaempf A, Savage SL, Schultz AMR, Wilmot B, Mcweeney S, Mori M, Traer E, Druker BJ, Tyner JW. Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia Blood. 130: 2068-2068. DOI: 10.1182/Blood.V130.Suppl_1.2068.2068  1
2017 Eide CA, Kurtz SE, Kaempf A, Park A, Rofelty A, Wilmot B, Bottomly D, McWeeney SK, Tognon CE, Mori M, Tyner JW, Druker BJ. Differential Ex Vivo Sensitivity Patterns to Small-Molecule Inhibitors and Combination Therapies Among Acute Myeloid Leukemia Patients Harboring Both FLT3 and NPM1 Mutations Blood. 130: 1422-1422. DOI: 10.1182/Blood.V130.Suppl_1.1422.1422  1
2017 Kurtz SE, Wilmot B, McWeeney S, Vellanki A, Local A, Benbatoul K, Folger P, Sheng S, Zhang H, Howell SB, Rice WG, Druker BJ, Tyner JW. Abstract 44: CG′806, a first-in-class FLT3/BTK inhibitor, exhibits potent activity against AML patient samples with mutant or wild type FLT3, as well as other hematologic malignancy subtypes Clinical Cancer Research. 23: 44-44. DOI: 10.1158/1557-3265.Hemmal17-44  1
2017 Gupta P, Kathawala R, Wei L, Wang F, Wang X, Druker BJ, Fu L, Chen Z. Abstract 4158: Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor Cancer Research. 77: 4158-4158. DOI: 10.1158/1538-7445.Am2017-4158  1
2016 Raess PW, Cascio MJ, Fan G, Press R, Druker BJ, Brewer D, Spurgeon SE. Concurrent STAT3, DNMT3A and TET2 mutations in T-LGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. American Journal of Hematology. PMID 27761930 DOI: 10.1002/Ajh.24586  1
2016 Gupta P, Kathawala RJ, Wei L, Wang F, Wang X, Druker BJ, Fu LW, Chen ZS. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Letters. PMID 27720778 DOI: 10.1016/J.Canlet.2016.09.025  1
2016 Traer E, Martinez J, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner JW, Wong M, Druker BJ. FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia. Cancer Research. PMID 27671675 DOI: 10.1158/0008-5472.Can-15-3569  1
2016 Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia. Science Translational Medicine. 8: 354ra114. PMID 27582059 DOI: 10.1126/Scitranslmed.Aaf5309  1
2016 Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gönen M, Tyner JW, Druker BJ, Vu TQ. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Scientific Reports. 6: 28163. PMID 27320899 DOI: 10.1038/Srep28163  1
2016 Wiedmeier JE, Kato C, Zhang Z, Lee H, Dunlap J, Nutt E, Rattray R, McKay S, Eide C, Press R, Mori M, Druker B, Dao KH. Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women. Experimental Hematology. PMID 27235757 DOI: 10.1016/J.Exphem.2016.05.009  1
2016 Watanabe-Smith K, Tognon C, Tyner JW, Meijerink JP, Druker BJ, Agarwal A. Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia. Leukemia. PMID 27118405 DOI: 10.1038/Leu.2016.95  1
2016 de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, Duarte AD, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. Oncotarget. PMID 26755644 DOI: 10.18632/Oncotarget.6851  1
2016 Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Druker BJ, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6  1
2016 Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Mori M, Traer E, Druker BJ, Tyner JW. Identification of Effective Combinations of Targeted Drugs for Hematologic Malignancies Blood. 128: 836-836. DOI: 10.1182/Blood.V128.22.836.836  1
2016 Puri A, Mahmood S, Maertens B, Davare M, Kurtz SE, Tognon CE, Eden CO, Elferich J, Shinde U, Druker BJ, Singer JW, Agarwal A. Pacritinib Targets IRAK1 and Shows Synergy with HDAC and BET Inhibitors in Acute Myeloid Leukemia Blood. 128: 3514-3514. DOI: 10.1182/Blood.V128.22.3514.3514  1
2016 Qian K, Tognon CE, Wagner J, Davare M, Druker BJ. Characterization of Transforming NTRK2 and NTRK3 Mutations Identified in Leukemia Patient Samples Blood. 128: 1566-1566. DOI: 10.1182/Blood.V128.22.1566.1566  1
2016 English IA, Martinez J, Rassi EE, Schmidt M, Langer E, Bornstein S, Gleysteen J, Wong M, Druker B, Traer E. Abstract 1631: FGF2 activation of FGFR1 in head and neck squamous cell carcinoma is associated with more invasive disease and can be attenuated by FGFR inhibition Cancer Research. 76: 1631-1631. DOI: 10.1158/1538-7445.Am2016-1631  1
2015 Khanna V, Pierce ST, Dao KH, Tognon CE, Hunt DE, Junio B, Tyner JW, Druker BJ. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. CurēUs. 7: e414. PMID 26870618 DOI: 10.7759/Cureus.414  1
2015 Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D, Wilmot B, McWeeney SK, Radich J, Hantschel O, Middleton RE, ... ... Druker BJ, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Research. PMID 26677978 DOI: 10.1158/0008-5472.Can-15-0817  1
2015 Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26673800 DOI: 10.1158/1078-0432.Ccr-15-2013  1
2015 Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, Pomicter AD, Reynolds KR, Eiring AM, Kronenberg Z, Sherman RL, Tyner JW, Dalley BK, Dao KH, Yandell M, ... Druker BJ, et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. PMID 26648538 DOI: 10.1038/Leu.2015.337  1
2015 Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 132: 2248-58. PMID 26644247 DOI: 10.1161/Circulationaha.115.010484  0.01
2015 Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, O'Hare T. Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia. Leukemia. PMID 26582647 DOI: 10.1038/Leu.2015.318  1
2015 Garbati MR, Welgan CA, Landefeld SH, Newell LF, Agarwal A, Dunlap JB, Chourasia TK, Lee H, Elferich J, Traer E, Rattray R, Cascio MJ, Press RD, Bagby GC, Tyner JW, ... Druker BJ, et al. Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism. American Journal of Hematology. PMID 26573090 DOI: 10.1002/Ajh.24245  1
2015 Brooks SA, Luty SB, Lai HY, Morse SJ, Nguyen TK, Royer LR, Agarwal A, Druker BJ, Fleischman AG. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. Experimental Hematology. PMID 26458983 DOI: 10.1016/J.Exphem.2015.09.006  1
2015 Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ. Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. PMID 26372962 DOI: 10.1073/Pnas.1515281112  1
2015 Siegel MB, Liu SQ, Davare MA, Spurgeon SE, Loriaux MM, Druker BJ, Scott EC, Tyner JW. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Oncotarget. PMID 26254279 DOI: 10.18632/Oncotarget.4214  1
2015 Paten B, Diekhans M, Druker BJ, Friend S, Guinney J, Gassner N, Guttman M, James Kent W, Mantey P, Margolin AA, Massie M, Novak AM, Nothaft F, Pachter L, Patterson D, et al. The NIH BD2K center for big data in translational genomics. Journal of the American Medical Informatics Association : Jamia. PMID 26174866 DOI: 10.1093/Jamia/Ocv047  1
2015 Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW. Therapeutically Targetable ALK Mutations in Leukemia. Cancer Research. 75: 2146-50. PMID 26032424 DOI: 10.1158/0008-5472.Can-14-1576  1
2015 Chang BH, Johnson K, LaTocha D, Rowley JS, Bryant J, Burke R, Smith RL, Loriaux M, Müschen M, Mullighan C, Druker BJ, Tyner JW. YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway. Journal of Hematology & Oncology. 8: 39. PMID 25895498 DOI: 10.1186/S13045-015-0132-6  1
2015 Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Druker BJ, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003  1
2015 Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, Druker BJ, McCarty OJ. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thrombosis Research. 135: 155-60. PMID 25527332 DOI: 10.1016/J.Thromres.2014.11.009  1
2015 Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Research. 75: 880-91. PMID 25432174 DOI: 10.1158/0008-5472.Can-14-0573  1
2015 Beer PA, Knapp DJ, Miller PH, Kannan N, Sloma I, Heel K, Babovic S, Bulaeva E, Rabu G, Terry J, Druker BJ, Loriaux MM, Loeb KR, Radich JP, Erber WN, et al. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood. 125: 504-15. PMID 25370416 DOI: 10.1182/Blood-2014-06-581173  1
2015 Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. Oncogene. 34: 2991-9. PMID 25109334 DOI: 10.1038/Onc.2014.243  1
2015 Martinez J, Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Kovacsovics T, Tyner J, Wong M, Druker B. Abstract 984: FGF2 from the bone marrow promotes resistance to FLT3 inhibitors in AML Cancer Research. 75: 984-984. DOI: 10.1158/1538-7445.Am2015-984  1
2014 Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, ... ... Druker BJ, et al. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 124: 3260-73. PMID 25293778 DOI: 10.1182/Blood-2013-04-497040  1
2014 Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Science Translational Medicine. 6: 252ra121. PMID 25186176 DOI: 10.1126/Scitranslmed.3009073  1
2014 Dao KH, Solti MB, Maxson JE, Winton EF, Press RD, Druker BJ, Tyner JW. Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Research Reports. 3: 67-9. PMID 25180155 DOI: 10.1016/J.Lrr.2014.07.002  1
2014 Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, ... ... Druker BJ, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 26: 428-42. PMID 25132497 DOI: 10.1016/J.Ccr.2014.07.006  1
2014 Aslam MI, Abraham J, Mansoor A, Druker BJ, Tyner JW, Keller C. PDGFRβ reverses EphB4 signaling in alveolar rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: 6383-8. PMID 24733895 DOI: 10.1073/Pnas.1403608111  1
2014 Burke RT, Meadows S, Loriaux MM, Currie KS, Mitchell SA, Maciejewski P, Clarke AS, Dipaolo JA, Druker BJ, Lannutti BJ, Spurgeon SE. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget. 5: 908-15. PMID 24659719 DOI: 10.18632/Oncotarget.1484  1
2014 Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology. 99: 616-24. PMID 24658916 DOI: 10.1007/S12185-014-1566-2  1
2014 Druker BJ. Janet Rowley (1925-2013). Nature. 505: 484. PMID 24451535 DOI: 10.1038/505484A  0.01
2014 Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2092-103. PMID 24436473 DOI: 10.1158/1078-0432.Ccr-13-2575  1
2014 Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, English I, Martinez J, Tyner JW, Wong M, Druker BJ. Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations. Blood. 123: 1516-24. PMID 24408322 DOI: 10.1182/Blood-2013-07-518381  1
2014 Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. The Journal of Biological Chemistry. 289: 5820-7. PMID 24403076 DOI: 10.1074/Jbc.M113.508440  1
2014 Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. British Journal of Haematology. 164: 223-32. PMID 24383843 DOI: 10.1111/Bjh.12618  1
2014 Druker BJ. Imatinib as a paradigm of targeted cancer therapies Hamdan Medical Journal. 7. DOI: 10.7707/Hmj.394  0.01
2014 Agarwal A, Carey A, Traer E, Tyner J, Bagby GC, Druker BJ. Abstract 5248: Targeted suppression of interleukin-1 signaling inhibits growth of primary human acute myeloid leukemia cells Cancer Research. 74: 5248-5248. DOI: 10.1158/1538-7445.Am2014-5248  1
2014 Keck J, Druker B. Abstract 4772: Novel transforming ErbB2 mutations in leukemia Cancer Research. 74: 4772-4772. DOI: 10.1158/1538-7445.Am2014-4772  0.01
2014 Maxson J, Luty S, MacManiman J, Savage S, Abel M, Bahamadi S, Druker B, Tyner J. Abstract 2760: CSF3R ligand-independent mutations found in chronic neutrophilic leukemia have altered O-linked glycosylation Cancer Research. 74: 2760-2760. DOI: 10.1158/1538-7445.Am2014-2760  1
2013 Bottomly D, Ryabinin PA, Tyner JW, Chang BH, Loriaux MM, Druker BJ, McWeeney SK, Wilmot B. Comparison of methods to identify aberrant expression patterns in individual patients: augmenting our toolkit for precision medicine. Genome Medicine. 5: 103. PMID 24286512 DOI: 10.1186/Gm509  1
2013 Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ. Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proceedings of the National Academy of Sciences of the United States of America. 110: 19519-24. PMID 24218589 DOI: 10.1073/Pnas.1319583110  1
2013 Saborowski A, Saborowski M, Davare MA, Druker BJ, Klimstra DS, Lowe SW. Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proceedings of the National Academy of Sciences of the United States of America. 110: 19513-8. PMID 24154728 DOI: 10.1073/Pnas.1311707110  1
2013 Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 122: 3628-31. PMID 24081659 DOI: 10.1182/Blood-2013-06-509976  1
2013 Vainstein V, Eide CA, O'Hare T, Shukron O, Druker BJ. Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia. Blood. 122: 3331-4. PMID 24062017 DOI: 10.1182/Blood-2012-08-452409  1
2013 Eide CA, Druker BJ, O'Hare T. Kinase inhibitor therapy in CML: it's what's inside that counts. Oncotarget. 4: 1332-3. PMID 23934763 DOI: 10.18632/Oncotarget.1271  1
2013 Aslam MI, Hettmer S, Abraham J, Latocha D, Soundararajan A, Huang ET, Goros MW, Michalek JE, Wang S, Mansoor A, Druker BJ, Wagers AJ, Tyner JW, Keller C. Dynamic and nuclear expression of PDGFRα and IGF-1R in alveolar Rhabdomyosarcoma. Molecular Cancer Research : McR. 11: 1303-13. PMID 23928059 DOI: 10.1158/1541-7786.Mcr-12-0598  1
2013 Prins RC, Burke RT, Tyner JW, Druker BJ, Loriaux MM, Spurgeon SE. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway Leukemia. 27: 2094-2096. PMID 23900138 DOI: 10.1038/Leu.2013.228  1
2013 Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Research. 73: 5775-86. PMID 23887971 DOI: 10.1158/0008-5472.Can-13-1318  1
2013 Dao KH, Rotelli MD, Brown BR, Yates JE, Rantala J, Tognon C, Tyner JW, Druker BJ, Bagby GC. The PI3K/Akt1 pathway enhances steady-state levels of FANCL. Molecular Biology of the Cell. 24: 2582-92. PMID 23783032 DOI: 10.1091/Mbc.E13-03-0144  1
2013 Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, ... ... Druker BJ, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. The New England Journal of Medicine. 368: 1781-90. PMID 23656643 DOI: 10.1056/Nejmoa1214514  1
2013 Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J, Laneuville P, Larson R, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Blood. 121: 4439-4442. PMID 23620577 DOI: 10.1182/Blood-2013-03-490003  1
2013 O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, ... ... Druker BJ, et al. Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Research. 73: 3356-70. PMID 23576564 DOI: 10.1158/0008-5472.Can-12-3904  1
2013 Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Translational Oncology. 6: 158-68. PMID 23544168 DOI: 10.1593/Tlo.12307  1
2013 Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, ... ... Druker BJ, et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discovery. 3: 564-77. PMID 23471820 DOI: 10.1158/2159-8290.Cd-12-0504  1
2013 Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK. HitWalker: variant prioritization for personalized functional cancer genomics. Bioinformatics (Oxford, England). 29: 509-10. PMID 23303510 DOI: 10.1093/Bioinformatics/Btt003  1
2013 Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, ... ... Druker BJ, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 121: 489-98. PMID 23223358 DOI: 10.1182/Blood-2012-05-431379  1
2013 Spurgeon SE, Coffey G, Fletcher LB, Burke R, Tyner JW, Druker BJ, Betz A, DeGuzman F, Pak Y, Baker D, Pandey A, Hollenbach SJ, Sinha U, Loriaux MM. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia. The Journal of Pharmacology and Experimental Therapeutics. 344: 378-87. PMID 23220742 DOI: 10.1124/Jpet.112.200832  1
2013 Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, ... ... Druker BJ, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Research. 73: 285-96. PMID 23087056 DOI: 10.1158/0008-5472.Can-12-1906  1
2013 Traer E, Javidi-Sharifi N, Agarwal A, Dunlap J, Tyner J, Wong M, Druker B. Abstract 4971: FGF2 promotes resistance to ABL kinase inhibitors in CML. Cancer Research. 73: 4971-4971. DOI: 10.1158/1538-7445.Am2013-4971  1
2013 Agarwal A, MacKenzie R, Braziel R, Tyner JW, Druker BJ. Abstract 2333: Functional RNAi screen identifies novel cytokine and growth factor receptors critical for the growth of leukemia patient samples. Cancer Research. 73: 2333-2333. DOI: 10.1158/1538-7445.Am2013-2333  1
2013 Maxson J, Gotlib J, Pollyea D, Fleischman A, Eide C, Bottomly D, Wilmot B, McWeeney S, Tognon C, Pond JB, Collins R, Deininger M, Chang B, Loriaux M, Druker B, et al. Abstract 2282: Rapid identification of targetable CSF3R mutations that define neutrophilic leukemia by combining functional and genomic screens. Cancer Research. 73: 2282-2282. DOI: 10.1158/1538-7445.Am2013-2282  1
2013 Dao K, Rotelli M, Brown B, Yates J, Rantala J, Tognon C, Tyner J, Druker B, Bagby G. The PI3K/Akt1 pathway enhances steady state levels of FANCL Experimental Hematology. 41. DOI: 10.1016/J.Exphem.2013.05.165  1
2012 Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 367: 2075-88. PMID 23190221 DOI: 10.1056/Nejmoa1205127  1
2012 Bicocca VT, Chang BH, Masouleh BK, Muschen M, Loriaux MM, Druker BJ, Tyner JW. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 22: 656-67. PMID 23153538 DOI: 10.1016/J.Ccr.2012.08.027  1
2012 Abraham J, Chua YX, Glover JM, Tyner JW, Loriaux MM, Kilcoyne A, Giles FJ, Nelon LD, Carew JS, Ouyang Y, Michalek JE, Pal R, Druker BJ, Rubin BP, Keller C. An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma. Biochemical and Biophysical Research Communications. 426: 363-8. PMID 22960170 DOI: 10.1016/J.Bbrc.2012.08.092  1
2012 Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 120: 3898-905. PMID 22915637 DOI: 10.1182/Blood-2012-02-410688  1
2012 Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood. 120: 2658-68. PMID 22889761 DOI: 10.1182/Blood-2011-05-355396  1
2012 Qiu X, Guo G, Chen K, Kashiwada M, Druker BJ, Rothman PB, Chen JL. A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia (New York, N.Y.). 14: 547-58. PMID 22787435 DOI: 10.1596/Neo.12230  1
2012 Dao KH, Rotelli MD, Petersen CL, Kaech S, Nelson WD, Yates JE, Hanlon Newell AE, Olson SB, Druker BJ, Bagby GC. FANCL ubiquitinates β-catenin and enhances its nuclear function. Blood. 120: 323-34. PMID 22653977 DOI: 10.1182/Blood-2011-11-388355  1
2012 Ryba T, Battaglia D, Chang BH, Shirley JW, Buckley Q, Pope BD, Devidas M, Druker BJ, Gilbert DM. Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. Genome Research. 22: 1833-44. PMID 22628462 DOI: 10.1101/Gr.138511.112  1
2012 Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatric Blood & Cancer. 59: 840-5. PMID 22378641 DOI: 10.1002/Pbc.24121  1
2012 Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 97: 731-8. PMID 22315495 DOI: 10.3324/Haematol.2011.045666  1
2012 Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, Camitta BM, Winick NJ, Druker BJ, Schultz KR. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. British Journal of Haematology. 157: 507-10. PMID 22299775 DOI: 10.1111/J.1365-2141.2012.09039.X  1
2012 Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, Druker BJ, Deininger MW. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors Leukemia. 26: 1140-1143. PMID 22094585 DOI: 10.1038/Leu.2011.325  1
2012 Glover JM, Loriaux M, Tyner JW, Druker BJ, Chang BH. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia. Pediatric Blood & Cancer. 59: 576-9. PMID 22038978 DOI: 10.1002/Pbc.23383  1
2012 Tyner JW, Jemal AM, Thayer M, Druker BJ, Chang BH. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia. Leukemia. 26: 623-32. PMID 21960246 DOI: 10.1038/Leu.2011.249  1
2012 Gilbert DM, Battaglia D, Chang BH, Buckley Q, Pope BD, Druker BJ, Ryba T. Replication Timing and Pediatric Leukemia Blood. 120: 4609-4609. DOI: 10.1182/Blood.V120.21.4609.4609  1
2011 Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell. 20: 715-27. PMID 22169110 DOI: 10.1016/J.Ccr.2011.11.004  1
2011 Zamah AM, Mauro MJ, Druker BJ, Oktay K, Egorin MJ, Cedars MI, Rosen MP. Will imatinib compromise reproductive capacity? The Oncologist. 16: 1422-7. PMID 21948652 DOI: 10.1634/Theoncologist.2011-0137  1
2011 Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim YM, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC, Hofmann WK, Hochhaus A, Ye BH, Agarwal A, Druker BJ, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of Experimental Medicine. 208: 2163-74. PMID 21911423 DOI: 10.1084/Jem.20110304  1
2011 O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 118: 5250-4. PMID 21908430 DOI: 10.1182/Blood-2011-05-349191  1
2011 Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, ... Druker BJ, et al. TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 118: 6392-8. PMID 21860020 DOI: 10.1182/Blood-2011-04-348144  1
2011 Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, Levine J, Neff TL, Patterson J, Presnell A, McKinley A, Winter LJ, Dewey C, Harlow A, Barney O, ... Druker BJ, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. The Journal of Molecular Diagnostics : Jmd. 13: 504-13. PMID 21726664 DOI: 10.1016/J.Jmoldx.2011.04.003  1
2011 Gu TL, Nardone J, Wang Y, Loriaux M, Villén J, Beausoleil S, Tucker M, Kornhauser J, Ren J, MacNeill J, Gygi SP, Druker BJ, Heinrich MC, Rush J, Polakiewicz RD. Survey of activated FLT3 signaling in leukemia. Plos One. 6: e19169. PMID 21552520 DOI: 10.1371/Journal.Pone.0019169  1
2011 Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Research. 71: 3189-95. PMID 21505103 DOI: 10.1158/0008-5472.Can-10-3224  1
2011 Gozgit JM, Wong MJ, Wardwell S, Tyner JW, Loriaux MM, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Druker BJ, Clackson T, Rivera VM. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Molecular Cancer Therapeutics. 10: 1028-35. PMID 21482694 DOI: 10.1158/1535-7163.Mct-10-1044  1
2011 Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. The Journal of Clinical Investigation. 121: 396-409. PMID 21157039 DOI: 10.1172/Jci35721  1
2011 O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ. Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 212-21. PMID 21098337 DOI: 10.1158/1078-0432.Ccr-09-3314  1
2011 Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 117: 591-4. PMID 20959606 DOI: 10.1182/Blood-2010-03-275305  1
2011 Hurtz C, Hatzi K, Cerchietti L, Park E, Kim Y, Ramezani-Rad P, Jumaa H, Muller MC, Hofmann W, Hochhaus A, Agarwal A, Shah N, Melnick A, Druker BJ, Muschen M. BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia Blood. 118: 446-446. DOI: 10.1182/Blood.V118.21.446.446  1
2011 Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI: 10.1172/JCI35721) Journal of Clinical Investigation. 121: 1222. DOI: 10.1172/Jci46407  1
2011 Sanda T, Tyner JW, Gutierrez A, Ngo VN, Moriggl R, Ahn Y, Glover J, Chang BH, Willis SG, Zhou W, Gray NS, Staudt LM, Druker BJ, Look AT. Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia Cancer Research. 71: 2809-2809. DOI: 10.1158/1538-7445.Am2011-2809  1
2010 Seo JH, Wood LJ, Agarwal A, O'Hare T, Elsea CR, Griswold IJ, Deininger MW, Imamoto A, Druker BJ. A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Research. 70: 7325-35. PMID 20807813 DOI: 10.1158/0008-5472.Can-10-0607  1
2010 Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 116: 3758-65. PMID 20679528 DOI: 10.1182/Blood-2010-03-273979  1
2010 Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Research. 70: 6233-7. PMID 20670955 DOI: 10.1158/0008-5472.Can-10-0429  1
2010 Carayol N, Vakana E, Sassano A, Kaur S, Goussetis DJ, Glaser H, Druker BJ, Donato NJ, Altman JK, Barr S, Platanias LC. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. 107: 12469-74. PMID 20616057 DOI: 10.1073/pnas.1005114107  1
2010 Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J. Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell. 18: 74-87. PMID 20609354 DOI: 10.1016/J.Ccr.2010.04.025  1
2010 Bumm T, Deininger J, Newell AH, Lawce H, Olson S, Mauro M, Druker B, Deininger M. Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors. Leukemia. 24: 1525-8. PMID 20535153 DOI: 10.1038/Leu.2010.123  1
2010 Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 116: 3278-85. PMID 20519627 DOI: 10.1182/Blood-2008-10-183665  1
2010 Ross RL, Jones KD, Bennett RM, Ward RL, Druker BJ, Wood LJ. Preliminary Evidence of Increased Pain and Elevated Cytokines in Fibromyalgia Patients with Defective Growth Hormone Response to Exercise. The Open Immunology Journal. 3: 9-18. PMID 20467575 DOI: 10.2174/1874226201003010009  1
2010 Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 115: 5232-40. PMID 20385788 DOI: 10.1182/Blood-2009-05-223727  1
2010 Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 424-30. PMID 20008622 DOI: 10.1200/Jco.2009.25.3724  1
2010 McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, O'Brien SG, Melo JV, Lange T, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 115: 315-25. PMID 19837975 DOI: 10.1182/Blood-2009-03-210732  1
2010 Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW. The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis. Leukemia. 24: 226-9. PMID 19759561 DOI: 10.1038/Leu.2009.196  1
2010 Wood LJ, Elsea CR, Nail LM, Winters KA, Druker BJ. Abstract B36: Induction of IL-6 by breast cancer chemotherapy mediates loss of fat-free lean body mass in tumor-free mice by decreasing systemic IGF-1 Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-B36  1
2010 Wood LJ, Nail LM, Elsea CR, Druker BJ. Abstract B35: Serum inflammatory biomarkers of acute and persistent fatigue in a preclinical breast cancer treatment model Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcme10-B35  1
2010 Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (Cancer (2009) 115 (551-160)) Cancer. 116: 3750. DOI: 10.1002/cncr.25358  1
2009 O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, ... ... Druker BJ, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 16: 401-12. PMID 19878872 DOI: 10.1016/J.Ccr.2009.09.028  1
2009 Johnson KJ, Griswold IJ, O'Hare T, Corbin AS, Loriaux M, Deininger MW, Druker BJ. A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice. Plos One. 4: e7439. PMID 19823681 DOI: 10.1182/Blood.V104.11.718.718  1
2009 Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nature Medicine. 15: 1149-52. PMID 19812576 DOI: 10.1038/Nm1009-1149  0.01
2009 Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 114: 4944-53. PMID 19779040 DOI: 10.1182/Blood-2009-04-214221  1
2009 Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood. 114: 3459-63. PMID 19706883 DOI: 10.1182/Blood-2007-10-113969  1
2009 Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O'Brien SG. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica. 94: 1669-75. PMID 19648168 DOI: 10.3324/Haematol.2009.010629  1
2009 Tyner J, Druker BJ. RNAi screen for therapeutic target in leukemia. Cell Cycle (Georgetown, Tex.). 8: 2144. PMID 19587534  1
2009 Scholl B, Liu HY, Long BR, McCarty OJ, O'Hare T, Druker BJ, Vu TQ. Single particle quantum dot imaging achieves ultrasensitive detection capabilities for Western immunoblot analysis. Acs Nano. 3: 1318-28. PMID 19453141 DOI: 10.1021/Nn9000353  1
2009 Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proceedings of the National Academy of Sciences of the United States of America. 106: 8695-700. PMID 19433805 DOI: 10.1073/Pnas.0903233106  1
2009 Tyner JW, Rutenberg-Schoenberg ML, Erickson H, Willis SG, O'Hare T, Deininger MW, Druker BJ, Loriaux MM. Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation. Leukemia. 23: 1345-8. PMID 19340004 DOI: 10.1038/Leu.2009.66  1
2009 Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia. 23: 1054-1061. PMID 19282833 DOI: 10.1038/Leu.2009.38  1
2009 Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, Krahnke T, Cortes J, Druker BJ. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 115: 551-60. PMID 19117345 DOI: 10.1002/Cncr.24066  1
2009 Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 113: 1749-55. PMID 19075190 DOI: 10.1182/Blood-2008-04-152157  1
2009 Tyner JW, Loriaux MM, Erickson H, Eide CA, Deininger J, MacPartlin M, Willis SG, Lange T, Druker BJ, Kovacsovics T, Maziarz R, Gattermann N, Deininger MW. High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia. Leukemia. 23: 406-9. PMID 18615102 DOI: 10.1038/Leu.2008.187  1
2009 Aichberger KJ, Fleischman AG, Doratotaj S, Bumm TGP, Silver RT, Deloughery TG, Pahl HL, Druker BJ, Burns CJ, Deininger M. Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F. Blood. 114: 2917-2917. DOI: 10.1182/Blood.V114.22.2917.2917  1
2009 Kim D, Granvil C, Demirhan E, Reynolds J, Jin Y, Wang Y, Baccarani M, Cortes-Franco J, Druker BJ, Hughes TP, Guilhot F. Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study. Blood. 114: 1127-1127. DOI: 10.1182/Blood.V114.22.1127.1127  1
2008 Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 112: 4808-17. PMID 19064740 DOI: 10.1182/Blood-2008-07-077958  0.01
2008 Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM. Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate. Plos One. 3: e3593. PMID 18974832 DOI: 10.1371/Journal.Pone.0003593  1
2008 Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST. Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Molecular and Cellular Biology. 28: 6496-509. PMID 18694961 DOI: 10.1128/Mcb.00477-08  1
2008 Agarwal A, Bumm TGP, Corbin AS, O'Hare T, Loriaux M, Van Dyke J, Willis SG, Deininger J, Nakayama KI, Druker BJ, Deininger MW. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease Blood. 112: 1960-1970. PMID 18559973 DOI: 10.1182/Blood-2007-09-113860  1
2008 MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW. Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells. Leukemia. 22: 1354-60. PMID 18548107 DOI: 10.1038/Leu.2008.126  1
2008 Elsea CR, Roberts DA, Druker BJ, Wood LJ. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. Plos One. 3: e2355. PMID 18523641 DOI: 10.1371/Journal.Pone.0002355  1
2008 Agarwal A, Eide CA, Harlow A, Corbin AS, Mauro MJ, Druker BJ, Corless CL, Heinrich MC, Deininger MW. An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia. 22: 2269-72. PMID 18509354 DOI: 10.1038/Leu.2008.124  1
2008 Katsoulidis E, Sassano A, Majchrzak-Kita B, Carayol N, Yoon P, Jordan A, Druker BJ, Fish EN, Platanias LC. Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. The Journal of Biological Chemistry. 283: 10793-803. PMID 18287094 DOI: 10.1074/Jbc.M706816200  1
2008 Laudadio J, Deininger MW, Mauro MJ, Druker BJ, Press RD. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. The Journal of Molecular Diagnostics : Jmd. 10: 177-80. PMID 18276770 DOI: 10.2353/Jmoldx.2008.070128  1
2008 Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T, Gathmann I, Wang Y. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 111: 4022-8. PMID 18256322 DOI: 10.1182/Blood-2007-10-116475  1
2008 Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, ... ... Druker BJ, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood. 111: 4788-96. PMID 18252861 DOI: 10.1182/Blood-2007-07-101394  1
2008 Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC. Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. The Journal of Biological Chemistry. 283: 8601-10. PMID 18223253 DOI: 10.1074/Jbc.M707934200  1
2008 Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 111: 2238-45. PMID 18025156 DOI: 10.1182/Blood-2007-06-097253  1
2008 Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J, Niederwieser DW, Gambacorti-Passerini C, Gambacorti C, Stone RM, Goldman J, Fischer T, O'Brien SG, Reiffers JJ, Mone M, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 111: 1039-43. PMID 17932248 DOI: 10.1182/Blood-2007-07-103523  1
2008 Müller MC, Cortes J, Kim D, Druker BJ, Erben P, Pasquini R, Hughes TP, Matloub Y, Ploughman L, Hochhaus A. Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations Blood. 112: 449-449. DOI: 10.1182/Blood.V112.11.449.449  1
2008 Cortes J, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim D, Pane F, Rudoltz M, Yu R, Collins L, Krahnke T, Radich JP, Hughes TP. A Phase III, Randomized, Open-Label Study of 400 Mg Versus 800 Mg of Imatinib Mesylate (IM) in Patients (pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Using Molecular Endpoints: 1-Year Results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study Blood. 112: 335-335. DOI: 10.1182/Blood.V112.11.335.335  1
2008 Hughes TP, Hochhaus A, Branford S, Müller MC, Foroni L, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Waltzman RJ, Mone M, Wehrle E, Radich JP, Goldman JM. Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP) Blood. 112: 334-334. DOI: 10.1182/Blood.V112.11.334.334  1
2008 Hasford J, Lauseker M, Gathmann I, Pfirrmann M, Larson RA, Guilhot F, O’Brien SG, Druker BJ, Hehlmann R, Hochhaus A. Favorable Outcome of Chronic Myeloid Leukemia Patients Treated with Imatinib Vs Early Allogeneic Stem Cell Transplantation. Blood. 112: 2123-2123. DOI: 10.1182/Blood.V112.11.2123.2123  1
2008 O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Rudoltz M, Filian J, Gathmann I, Druker BJ, Larson RA. International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM) Blood. 112: 186-186. DOI: 10.1182/Blood.V112.11.186.186  1
2007 Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, ... ... Druker BJ, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 12: 501-13. PMID 18068628 DOI: 10.1016/J.CCR.2007.11.005  1
2007 Thomas EK, Cancelas JA, Chae HD, Cox AD, Keller PJ, Perrotti D, Neviani P, Druker BJ, Setchell KD, Zheng Y, Harris CE, Williams DA. Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell. 12: 467-78. PMID 17996650 DOI: 10.1016/J.Ccr.2007.10.015  1
2007 Choong LY, Lim S, Loh MC, Man X, Chen Y, Toy W, Pan M, Chen CS, Poonepalli A, Hande MP, Tan PH, Salto-Tellez M, Wong CY, Shah N, Druker BJ, et al. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics. Molecular Cancer Therapeutics. 6: 2828-42. PMID 17989321 DOI: 10.1158/1535-7163.Mct-06-0809  1
2007 Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6136-43. PMID 17947479 DOI: 10.1158/1078-0432.Ccr-07-1112  1
2007 Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, Tan YL, Loh MC, Hew CL, Shah N, Druker BJ, Chong PK, Lim YP. Differential expression of novel tyrosine kinase substrates during breast cancer development. Molecular & Cellular Proteomics : McP. 6: 2072-87. PMID 17855441 DOI: 10.1074/Mcp.M700395-Mcp200  1
2007 Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. The Journal of Clinical Investigation. 117: 2408-21. PMID 17717597 DOI: 10.1172/Jci31095  1
2007 Blasdel C, Egorin MJ, Lagattuta TF, Druker BJ, Deininger MW. Therapeutic drug monitoring in CML patients on imatinib. Blood. 110: 1699-701; author rep. PMID 17712052 DOI: 10.1182/Blood-2007-03-079871  1
2007 Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M, Stone R, Fischer T, Kantarjian H, Niederwieser D, Gambacorti-Passerini C, So C, Gathmann I, Goldman JM, Smith D, ... Druker BJ, et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer. 110: 1509-19. PMID 17702093 DOI: 10.1002/Cncr.22936  1
2007 Sherbenou DW, Druker BJ. Applying the discovery of the Philadelphia chromosome. The Journal of Clinical Investigation. 117: 2067-74. PMID 17671641 DOI: 10.1172/Jci31988  1
2007 Reddi AL, Ying G, Duan L, Chen G, Dimri M, Douillard P, Druker BJ, Naramura M, Band V, Band H. Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation. The Journal of Biological Chemistry. 282: 29336-47. PMID 17620338 DOI: 10.1074/Jbc.M701797200  1
2007 Chen Y, Low TY, Choong LY, Ray RS, Tan YL, Toy W, Lin Q, Ang BK, Wong CH, Lim S, Li B, Hew CL, Sze NS, Druker BJ, Lim YP. Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells. Proteomics. 7: 2384-97. PMID 17570516 DOI: 10.1002/Pmic.200600968  1
2007 Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 110: 323-33. PMID 17360941 DOI: 10.1182/Blood-2006-10-052282  1
2007 Sherbenou DW, Wong MJ, Humayun A, McGreevey LS, Harrell P, Yang R, Mauro M, Heinrich MC, Press RD, Druker BJ, Deininger MW. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia. 21: 489-93. PMID 17252009 DOI: 10.1038/Sj.Leu.2404554  1
2007 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109: 2303-9. PMID 17138817 DOI: 10.1182/Blood-2006-09-047266  1
2007 Chen J, Yu WM, Daino H, Broxmeyer HE, Druker BJ, Qu CK. SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood. 109: 778-85. PMID 17003374 DOI: 10.1182/Blood-2006-04-019141  0.01
2007 Agarwal A, Eide CA, Harlow A, Tyner JW, Mauro MJ, Corless CL, Heinrich MC, Druker BJ, Deininger MW. An Activating KRAS Mutation in Imatinib Resistant Chronic Myeloid Leukemia. Blood. 110: 1006-1006. DOI: 10.1182/Blood.V110.11.1006.1006  1
2006 Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 355: 2408-17. PMID 17151364 DOI: 10.1056/Nejmoa062867  1
2006 Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Research. 66: 11156-65. PMID 17145859 DOI: 10.1158/0008-5472.Can-06-2210  1
2006 La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6540-6. PMID 17085669 DOI: 10.1158/1078-0432.Ccr-06-0140  1
2006 Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biological Research For Nursing. 8: 157-69. PMID 17003255 DOI: 10.1177/1099800406290932  1
2006 Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America. 103: 14907-12. PMID 16997913 DOI: 10.1073/Pnas.0606176103  1
2006 Gu TL, Goss VL, Reeves C, Popova L, Nardone J, Macneill J, Walters DK, Wang Y, Rush J, Comb MJ, Druker BJ, Polakiewicz RD. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 108: 4202-4. PMID 16946300 DOI: 10.1182/Blood-2006-06-026666  1
2006 DeAngelo DJ, Stone RM, Heaney ML, Nimer SD, Paquette RL, Klisovic RB, Caligiuri MA, Cooper MR, Lecerf JM, Karol MD, Sheng S, Holford N, Curtin PT, Druker BJ, Heinrich MC. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 108: 3674-81. PMID 16902153 DOI: 10.1182/Blood-2006-02-005702  1
2006 Griswold IJ, MacPartlin M, Bumm T, Goss VL, O'Hare T, Lee KA, Corbin AS, Stoffregen EP, Smith C, Johnson K, Moseson EM, Wood LJ, Polakiewicz RD, Druker BJ, Deininger MW. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib Molecular and Cellular Biology. 26: 6082-6093. PMID 16880519 DOI: 10.1182/Blood.V108.11.4796.4796  1
2006 Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA, Crispino J, ... ... Druker BJ, et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell. 10: 65-75. PMID 16843266 DOI: 10.1016/J.Ccr.2006.06.002  1
2006 Druker BJ. Circumventing resistance to kinase-inhibitor therapy. The New England Journal of Medicine. 354: 2594-6. PMID 16775240 DOI: 10.1056/Nejme068073  0.01
2006 Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY, Druker BJ, Deininger MW. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 108: 2332-8. PMID 16772610 DOI: 10.1182/Blood-2006-02-004580  1
2006 Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2239-47. PMID 16609040 DOI: 10.1158/1078-0432.Ccr-05-2282  1
2006 Demehri S, Corbin A, Loriaux M, Druker BJ, Deininger MW. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Experimental Hematology. 34: 284-8. PMID 16543062 DOI: 10.1016/J.Exphem.2005.11.015  1
2006 Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 108: 28-37. PMID 16522812 DOI: 10.1182/Blood-2006-01-0092  1
2006 Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, Friend S, Linsley PS. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 103: 2794-9. PMID 16477019 DOI: 10.1073/Pnas.0510423103  1
2006 Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood. 107: 4250-6. PMID 16467199 DOI: 10.1182/Blood-2005-11-4406  1
2006 Walters DK, Goss VL, Stoffregen EP, Gu TL, Lee K, Nardone J, McGreevey L, Heinrich MC, Deininger MW, Polakiewicz R, Druker BJ. Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leukemia Research. 30: 1097-104. PMID 16464493 DOI: 10.1016/J.Leukres.2006.01.001  1
2006 Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Research. 66: 473-81. PMID 16397263 DOI: 10.1158/0008-5472.Can-05-2050  1
2006 O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Current Opinion in Genetics & Development. 16: 92-9. PMID 16343892 DOI: 10.1016/J.Gde.2005.11.002  1
2006 Larson RA, Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Riviere GJ, So C, Wang Y. Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib - An Analysis of IRIS Study Data. Blood. 108: 429-429. DOI: 10.1182/Blood.V108.11.429.429  1
2006 Baccarani M, Guilhot F, Larson RA, O’Brien SG, Druker BJ. Outcomes by Cytogenetic and Molecular Response at 12 and 18 Months of Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the IRIS Trial. Blood. 108: 2138-2138. DOI: 10.1182/Blood.V108.11.2138.2138  1
2006 Kantarjian HM, Larson RA, Guilhot F, O’Brien SG, Druker BJ. Declining Rates of Adverse Events (AEs), Rare Occurrence of Serious AEs (SAEs), and No Unexpected Long-Term Side Effects at 5 Years in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Initially Treated with Imatinib (IM) in the International Randomized Study of Interferon vs STI571 (IRIS). Blood. 108: 2136-2136. DOI: 10.1182/Blood.V108.11.2136.2136  1
2006 Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Erratum: Bim and Bad mediate imatinib-induced killing of Bcr/Abl leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic (Proceedings of the National Academy of Sciences of the United States of America (October 3, 2006) 40, 103 (14907-14912) DOI: 10.1073/pnas.0606176103) Proceedings of the National Academy of Sciences of the United States of America. 103. DOI: 10.1073/Pnas.0608594103  1
2005 Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ, Sillaber C, Esterbauer H, Valent P. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Research. 65: 9436-9444. PMID 16230407 DOI: 10.1158/0008-5472.Can-05-0972  1
2005 O'Hare T, Druker BJ. BIRB-796 is not an effective ABL(T315I) inhibitor. Nature Biotechnology. 23: 1209-10; author repl. PMID 16211050 DOI: 10.1038/Nbt1005-1209  1
2005 O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 6987-93. PMID 16203792 DOI: 10.1158/1078-0432.Ccr-05-0622  1
2005 Crossman LC, O'Hare T, Lange T, Willis SG, Stoffregen EP, Corbin AS, O'Brien SG, Heinrich MC, Druker BJ, Middleton PG, Deininger MWN. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib Leukemia. 19: 1859-1862. PMID 16151465 DOI: 10.1038/Sj.Leu.2403935  1
2005 Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, ... ... Druker B, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 106: 3377-9. PMID 16081687 DOI: 10.1182/Blood-2005-05-1898  1
2005 Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood. 106: 1133-4; author reply. PMID 16033955 DOI: 10.1182/Blood-2005-02-0694  1
2005 O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, Druker BJ. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Research. 65: 4500-5. PMID 15930265 DOI: 10.1158/0008-5472.Can-05-0259  1
2005 Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, Druker BJ, Deininger MW. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. 106: 2128-37. PMID 15914554 DOI: 10.1182/Blood-2005-03-1036  1
2005 Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, et al. Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 960-2. PMID 15784722 DOI: 10.1096/Fj.04-1973Fje  1
2005 Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood. 106: 227-34. PMID 15746079 DOI: 10.1182/Blood-2004-12-4771  1
2005 O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN107: tightening the grip of imatinib. Cancer Cell. 7: 117-9. PMID 15710324 DOI: 10.1016/J.Ccr.2005.01.020  1
2005 Demehri S, Paschka P, Schultheis B, Lange T, Koizumi T, Sugimoto T, Branford S, Lim LC, Kegel T, Martinelli G, Hochhaus A, Druker BJ, Deininger MW. e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants? Leukemia. 19: 681-4. PMID 15703785 DOI: 10.1038/Sj.Leu.2403604  1
2005 Tseng PH, Lin HP, Zhu J, Chen KF, Hade EM, Young DC, Byrd JC, Grever M, Johnson K, Druker BJ, Chen CS. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. Blood. 105: 4021-7. PMID 15665113 DOI: 10.1182/Blood-2004-07-2967  1
2005 Walters DK, Stoffregen EP, Heinrich MC, Deininger MW, Druker BJ. RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood. 105: 2952-4. PMID 15585651 DOI: 10.1182/Blood-2004-07-2758  1
2005 Deininger MWN, Bradeen H, Jia T, O’Hare T, Willis SG, Lee F, Druker BJ. Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen. Blood. 106: 691-691. DOI: 10.1182/Blood.V106.11.691.691  1
2004 Grossmann AH, Kolibaba KS, Willis SG, Corbin AS, Langdon W, Deininger MWN, Druker BJ. Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl Febs Letters. 577: 555-562. PMID 15556646 DOI: 10.1016/J.Febslet.2004.10.054  1
2004 Corbin AS, Griswold IJ, La Rosée P, Yee KW, Heinrich MC, Reimer CL, Druker BJ, Deininger MW. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood. 104: 3754-7. PMID 15304388 DOI: 10.1182/Blood-2004-06-2189  1
2004 O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, ... ... Druker BJ, et al. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood. 104: 2532-9. PMID 15256422 DOI: 10.1182/Blood-2004-05-1851  1
2004 Griswold IJ, Shen LJ, La Rosée P, Demehri S, Heinrich MC, Braziel RM, McGreevey L, Haley AD, Giese N, Druker BJ, Deininger MW. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis. Blood. 104: 2912-8. PMID 15242881 DOI: 10.1182/Blood-2003-05-1669  1
2004 Lim YP, Wong CY, Ooi LL, Druker BJ, Epstein RJ. Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3980-7. PMID 15217928 DOI: 10.1158/1078-0432.Ccr-03-0663  1
2004 Leis JF, Stepan DE, Curtin PT, Ford JM, Peng B, Schubach S, Druker BJ, Maziarz RT. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & Lymphoma. 45: 695-8. PMID 15160941 DOI: 10.1080/10428190310001625728  1
2004 Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 935-42. PMID 14990650 DOI: 10.1200/Jco.2004.03.050  1
2004 Deininger MWN, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography Leukemia. 18: 864-871. PMID 14973502 DOI: 10.1038/Sj.Leu.2403307  1
2004 Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker BJ, Deininger MW. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. The Hematology Journal : the Official Journal of the European Haematology Association / Eha. 5: 55-60. PMID 14745431 DOI: 10.1038/Sj.Thj.6200319  1
2004 O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, Mori M, Druker BJ. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate Blood. 103: 451-455. PMID 14512312 DOI: 10.1182/Blood-2003-02-0371  1
2004 La Rosée P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, Mauro MM, Melo JV, Deininger MW, Druker BJ. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 103: 208-15. PMID 12933582 DOI: 10.1182/Blood-2003-04-1074  1
2004 Griswold IJ, Bumm T, O’Hare T, Moseson EM, Druker BJ, Deininger MW. Investigation of the Biological Differences between Bcr-Abl Kinase Mutations Resistant to Imatinib. Blood. 104: 555-555. DOI: 10.1182/Blood.V104.11.555.555  1
2004 Norasetthada L, Maris MB, Sandmaier BM, Maloney DG, Georges G, Druker B, Radich J, Storb R. Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood. 104: 5056-5056. DOI: 10.1182/Blood.V104.11.5056.5056  1
2003 La Rosée P, Shen L, Stoffregen EP, Deininger M, Druker BJ. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec). The Hematology Journal : the Official Journal of the European Haematology Association. 4: 413-9. PMID 14671613 DOI: 10.1038/Sj.Thj.6200297  1
2003 Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 22: 8852-60. PMID 14654781 DOI: 10.1038/Sj.Onc.1206892  1
2003 Heinrich MC, Corless CL, Demetri GD, Blanke CD, Von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van Den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor Journal of Clinical Oncology. 21: 4342-4349. PMID 14645423 DOI: 10.1200/Jco.2003.04.190  1
2003 Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2138-46. PMID 12775739 DOI: 10.1200/JCO.2003.12.154  1
2003 Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 1637-47. PMID 12668652 DOI: 10.1200/JCO.2003.11.143  1
2003 O'Dwyer ME, Gatter KM, Loriaux M, Druker BJ, Olson SB, Magenis RE, Lawce H, Mauro MJ, Maziarz RT, Braziel RM. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate. Leukemia. 17: 481-7. PMID 12646934 DOI: 10.1038/Sj.Leu.2402848  1
2003 O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, ... ... Druker BJ, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine. 348: 994-1004. PMID 12637609 DOI: 10.1056/Nejmoa022457  1
2003 Corbin AS, La Rosée P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 101: 4611-4. PMID 12576318 DOI: 10.1182/Blood-2002-12-3659  1
2002 Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, Griffith DJ, Wait CL, Druker BJ, Heinrich MC, Nelson JA, Fruh K. A functional genomics approach to Kaposi's sarcoma. Annals of the New York Academy of Sciences. 975: 180-91. PMID 12538164 DOI: 10.1111/J.1749-6632.2002.Tb05951.X  1
2002 Druker BJ, O'Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 111-35. PMID 12446421 DOI: 10.1182/Asheducation-2002.1.111  1
2002 Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 100: 1965-71. PMID 12200353 DOI: 10.1182/Blood-2001-12-0181  1
2002 Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, ... ... Druker BJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. The New England Journal of Medicine. 347: 472-80. PMID 12181401 DOI: 10.1056/Nejmoa020461  1
2002 Rosée PL, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Experimental Hematology. 30: 729-737. PMID 12135670 DOI: 10.1016/S0301-472X(02)00836-6  1
2002 Moses AV, Jarvis MA, Raggo C, Bell YC, Ruhl R, Luukkonen BG, Griffith DJ, Wait CL, Druker BJ, Heinrich MC, Nelson JA, Früh K. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. Journal of Virology. 76: 8383-99. PMID 12134042 DOI: 10.1128/Jvi.76.16.8383-8399.2002  1
2002 Rosée PL, O'Dwyer M, Druker B. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia. 16: 1213-1219. PMID 12094245 DOI: 10.1038/Sj.Leu.2402555  1
2002 Corbin AS, Buchdunger E, Pascal F, Druker BJ. Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. Journal of Biological Chemistry. 277: 32214-32219. PMID 12077114 DOI: 10.1074/Jbc.M111525200  1
2002 Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, Lindahl K, Li S, Van Etten RA, Borrow J, Housman D, Druker B, Gilliland DG. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proceedings of the National Academy of Sciences of the United States of America. 99: 7622-7. PMID 12032333 DOI: 10.1073/Pnas.102583199  1
2002 O'Dwyer ME, La Rosée P, Nimmanapalli R, Bhalla KN, Druker BJ. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Seminars in Hematology. 39: 18-21. PMID 12012318 DOI: 10.1053/Shem.2002.33612  1
2002 Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, ... ... Druker BJ, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 99: 3530-9. PMID 11986204 DOI: 10.1182/Blood.V99.10.3530  1
2002 Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies Journal of Clinical Oncology. 20: 1692-1703. PMID 11896121 DOI: 10.1200/Jco.20.6.1692  1
2002 Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The New England Journal of Medicine. 346: 645-52. PMID 11870241 DOI: 10.1056/Nejmoa011573  1
2002 Lekmine F, Sassano A, Uddin S, Majchrzak B, Miura O, Druker BJ, Fish EN, Imamoto A, Platanias LC. The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1. Biochemical and Biophysical Research Communications. 291: 744-50. PMID 11866427 DOI: 10.1006/Bbrc.2002.6516  1
2002 Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: A paradigm of new agents for cancer therapeutics Journal of Clinical Oncology. 20: 325-334. PMID 11773186 DOI: 10.1200/Jco.20.1.325  1
2000 Wilbanks AM, Mahajan S, Frank DA, Druker BJ, Gilliland DG, Carroll M. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Experimental Hematology. 28: 584-93. PMID 10812249 DOI: 10.1016/S0301-472X(00)00138-7  1
2000 Rao N, Lupher ML, Ota S, Reedquist KA, Druker BJ, Band H. The Linker Phosphorylation Site Tyr292 Mediates the Negative Regulatory Effect of Cbl on ZAP-70 in T Cells Journal of Immunology. 164: 4616-4626. PMID 10779765 DOI: 10.4049/Jimmunol.164.9.4616  1
2000 Gaston I, Stenberg PE, Bhat A, Druker BJ. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells. Experimental Hematology. 28: 77-86. PMID 10658679 DOI: 10.1016/S0301-472X(99)00130-7  1
2000 Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells Blood. 96: 3195-3199. DOI: 10.1182/Blood.V96.9.3195.H8003195_3195_3199  1
2000 Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 96: 925-932. DOI: 10.1182/Blood.V96.3.925  1
2000 Oda A, Ikeda Y, Ochs HD, Druker BJ, Ozaki K, Handa M, Ariga T, Sakiyama Y, Witte ON, Wahl MI. Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood. 95: 1663-1670. DOI: 10.1182/Blood.V95.5.1663.005K44_1663_1670  1
1999 Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J, Druker B, Gilliland DG. TEL/PDGFβR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor Blood. 93: 1707-1714. PMID 10029600 DOI: 10.1182/Blood.V93.5.1707  1
1999 Oda A, Miyakawa Y, Druker BJ, Ozaki K, Ohashi H, Kato T, Miyazaki H, Handa M, Ikebuchi K, Ikeda Y. Thrombopoietin-induced signal transduction and potentiation of platelet activation Thrombosis and Haemostasis. 82: 377-384. DOI: 10.1055/S-0037-1615856  1
1998 Lupher ML, Rao N, Lill NL, Andoniou CE, Miyake S, Clark EA, Druker B, Band H. Cbl-mediated Negative Regulation of the Syk Tyrosine Kinase A CRITICAL ROLE FOR Cbl PHOSPHOTYROSINE-BINDING DOMAIN BINDING TO Syk PHOSPHOTYROSINE 323 Journal of Biological Chemistry. 273: 35273-35281. PMID 9857068 DOI: 10.1074/Jbc.273.52.35273  1
1998 Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ. Interactions of p62 dok with p210 bcr-abl and Bcr-Abl-associated Proteins Journal of Biological Chemistry. 273: 32360-32368. PMID 9822717 DOI: 10.1074/Jbc.273.48.32360  1
1998 Miyake S, Lupher ML, Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor α Proceedings of the National Academy of Sciences of the United States of America. 95: 7927-7932. PMID 9653117 DOI: 10.1073/Pnas.95.14.7927  1
1998 Oda A, Ochs HD, Druker BJ, Ozaki K, Watanabe C, Handa M, Miyakawa Y, Ikeda Y. Collagen Induces Tyrosine Phosphorylation of Wiskott-Aldrich Syndrome Protein in Human Platelets Blood. 92: 1852-1858. DOI: 10.1182/Blood.V92.6.1852.418K36_1852_1858  1
1998 Oda A, Sawada K, Druker BJ, Ozaki K, Takano H, Koizumi K, Fukada Y, Handa M, Koike T, Ikeda Y. Erythropoietin Induces Tyrosine Phosphorylation of Jak2, STAT5A, and STAT5B in Primary Cultured Human Erythroid Precursors Blood. 92: 443-451. DOI: 10.1182/Blood.V92.2.443.414K25_443_451  1
1998 Ozaki K, Oda A, Wakao H, Rhodes J, Druker BJ, Ishida A, Wakui M, Okamoto S, Morita K, Handa M, Komatsu N, Ohashi H, Miyajima A, Ikeda Y. Thrombopoietin Induces Association of Crkl With STAT5 But Not STAT3 in Human Platelets Blood. 92: 4652-4662. DOI: 10.1182/Blood.V92.12.4652  1
1997 Astier A, Manié SN, Law SF, Canty T, Haghayghi N, Druker BJ, Salgia R, Golemis EA, Freedman AS. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leukemia & Lymphoma. 28: 65-72. PMID 9498705 DOI: 10.3109/10428199709058332  1
1997 Pestina TI, Stenberg PE, Druker BJ, Steward SA, Hutson NK, Barrie RJ, Jackson CW. Identification of the Src family kinases, Lck and Fgr in platelets. Their tyrosine phosphorylation status and subcellular distribution compared with other Src family members. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 3278-85. PMID 9409323 DOI: 10.1161/01.Atv.17.11.3278  1
1997 Manié SN, Astier A, Haghayeghi N, Canty T, Druker BJ, Hirai H, Freedman AS. Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2. The Journal of Biological Chemistry. 272: 15636-41. PMID 9188452 DOI: 10.1074/Jbc.272.25.15636  1
1997 Manié SN, Beck AR, Astier A, Law SF, Canty T, Hirai H, Druker BJ, Avraham H, Haghayeghi N, Sattler M, Salgia R, Griffin JD, Golemis EA, Freedman AS. Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. The Journal of Biological Chemistry. 272: 4230-6. PMID 9020138 DOI: 10.1074/Jbc.272.7.4230  1
1997 Miyakawa Y, Oda A, Druker BJ, Ozaki K, Handa M, Ohashi H, Ikeda Y. Thrombopoietin and Thrombin Induce Tyrosine Phosphorylation of Vav in Human Blood Platelets Blood. 89: 2789-2798. DOI: 10.1182/Blood.V89.8.2789  1
1996 Hallek M, Danhauser-Riedl S, Herbst R, Warmuth M, Winkler A, Kolb HJ, Druker B, Griffin JD, Emmerich B, Ullrich A. Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells British Journal of Haematology. 94: 5-16. PMID 8757502 DOI: 10.1046/J.1365-2141.1996.6102053.X  0.01
1996 Egerton M, Moritz RL, Druker B, Kelso A, Simpson RJ. Identification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytes. Biochemical and Biophysical Research Communications. 224: 666-674. PMID 8713105 DOI: 10.1006/Bbrc.1996.1082  0.01
1996 Reedquist KA, Fukazawa T, Panchamoorthy G, Langdon WY, Shoelson SE, Druker BJ, Band H. Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G. The Journal of Biological Chemistry. 271: 8435-42. PMID 8626543 DOI: 10.1074/Jbc.271.14.8435  1
1996 Panchamoorthy G, Fukazawa T, Miyake S, Soltoff S, Reedquist K, Druker B, Shoelson S, Cantley L, Band H. p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with fyn and Syk tyrosine kinases, Grb2 and she adaptors, and the p85 subunit of phosphatidylinositol 3-kinase Journal of Biological Chemistry. 271: 3187-3194. PMID 8621719 DOI: 10.1074/Jbc.271.6.3187  1
1996 Oda A, Ozaki K, Druker BJ, Miyakawa Y, Miyazaki H, Handa M, Morita H, Ohashi H, Ikeda Y. p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin Blood. 88: 1330-1338. DOI: 10.1182/Blood.V88.4.1330.Bloodjournal8841330  1
1996 Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S, Ikeda Y. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin Blood. 88: 4304-4313. DOI: 10.1182/Blood.V88.11.4304.Bloodjournal88114304  1
1996 Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, Ikeda Y. Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets Blood. 87: 439-446. DOI: 10.1182/Blood.V87.2.439.Bloodjournal872439  1
1996 Oda A, Miyakawa Y, Druker BJ, Ozaki K, Yabusaki K, Shirasawa Y, Handa M, Kato T, Miyazaki H, Shimosaka A, Ikeda Y. Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists. Blood. 87: 4664-4670. DOI: 10.1182/Blood.V87.11.4664.Bloodjournal87114664  1
1995 Fukazawa T, Reedquist KA, Trub T, Soltoff S, Panchamoorthy G, Druker B, Cantley L, Shoelson SE, Band H. The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase. The Journal of Biological Chemistry. 270: 19141-50. PMID 7642581 DOI: 10.1074/Jbc.270.32.19141  1
1995 Fukazawa T, Reedquist KA, Panchamoorthy G, Soltoff S, Trub T, Druker B, Cantley L, Shoelson SE, Band H. T cell activation-dependent association between the p85 subunit of the phosphatidylinositol 3-kinase and Grb2/phospholipase C-gamma 1-binding phosphotyrosyl protein pp36/38. The Journal of Biological Chemistry. 270: 20177-82. PMID 7544353 DOI: 10.1074/Jbc.270.34.20177  1
1995 Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. The Journal of Biological Chemistry. 270: 29145-50. PMID 7493940 DOI: 10.1074/Jbc.270.49.29145  1
1995 Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, Ikeda Y. Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets Blood. 86: 23-27. DOI: 10.1182/Blood.V86.1.23.Bloodjournal86123  1
1994 Campbell KS, Ogris E, Burke B, Su W, Auger KR, Druker BJ, Schaffhausen BS, Roberts TM, Pallas DC. Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen Proceedings of the National Academy of Sciences of the United States of America. 91: 6344-6348. PMID 8022784 DOI: 10.1073/Pnas.91.14.6344  1
1994 Reedquist KA, Fukazawa T, Druker B, Panchamoorthy G, Shoelson SE, Band H. Rapid T-cell receptor-mediated tyrosine phosphorylation of p120, an Fyn/Lck Src homology 3 domain-binding protein. Proceedings of the National Academy of Sciences of the United States of America. 91: 4135-9. PMID 7514295 DOI: 10.1073/Pnas.91.10.4135  1
1992 Held JL, Druker BJ, Kohn SR, Byrnes W, Margolis RJ. Atypical, nonfatal, transfusion-associated, acute graft-versus-host disease in a patient with Hodgkin's disease. Journal of the American Academy of Dermatology. 26: 261-2. PMID 1552066 DOI: 10.1016/S0190-9622(08)80305-2  0.01
1992 Druker BJ, Sibert L, Roberts TM. Polyomavirus middle T-antigen NPTY mutants Journal of Virology. 66: 5770-5776. PMID 1326642 DOI: 10.1128/Jvi.66.10.5770-5776.1992  1
1991 Druker BJ, Roberts TM. Generation of a large library of point mutations in polymamiddle T antigen Nucleic Acids Research. 19: 6855-6861. PMID 1662365 DOI: 10.1093/Nar/19.24.6855  1
1981 Druker BJ, Wepsic HT, Alaimo J, Murray W. The negative systemic effect of BCGcw inoculated intraperitoneally Cancer Immunology, Immunotherapy. 10: 227-237. DOI: 10.1007/Bf00205524  0.01
Show low-probability matches.